FIL Ltd Sells 125,837 Shares of IQVIA Holdings Inc. (NYSE:IQV)

FIL Ltd reduced its stake in IQVIA Holdings Inc. (NYSE:IQV) by 17.3% during the fourth quarter, according to the company in its most recent 13F filing with the SEC. The fund owned 603,094 shares of the medical research company’s stock after selling 125,837 shares during the period. FIL Ltd’s holdings in IQVIA were worth $118,514,000 as of its most recent SEC filing.

Other hedge funds and other institutional investors have also made changes to their positions in the company. Benjamin Edwards Inc. bought a new position in IQVIA during the third quarter valued at approximately $261,000. Orion Portfolio Solutions LLC boosted its position in shares of IQVIA by 2.3% during the 3rd quarter. Orion Portfolio Solutions LLC now owns 16,319 shares of the medical research company’s stock valued at $3,867,000 after acquiring an additional 364 shares during the last quarter. Nomura Asset Management Co. Ltd. increased its position in IQVIA by 7.7% in the third quarter. Nomura Asset Management Co. Ltd. now owns 54,164 shares of the medical research company’s stock worth $12,835,000 after purchasing an additional 3,872 shares during the last quarter. Continuum Advisory LLC increased its position in IQVIA by 13.1% in the third quarter. Continuum Advisory LLC now owns 1,739 shares of the medical research company’s stock worth $412,000 after purchasing an additional 201 shares during the last quarter. Finally, MidWestOne Financial Group Inc. raised its stake in IQVIA by 5.1% during the third quarter. MidWestOne Financial Group Inc. now owns 4,786 shares of the medical research company’s stock valued at $1,134,000 after purchasing an additional 232 shares in the last quarter. Institutional investors own 89.62% of the company’s stock.

IQVIA Stock Down 5.9 %

Shares of NYSE IQV opened at $143.98 on Wednesday. IQVIA Holdings Inc. has a 52-week low of $138.87 and a 52-week high of $252.88. The firm has a market capitalization of $25.38 billion, a price-to-earnings ratio of 19.20, a PEG ratio of 1.99 and a beta of 1.46. The stock has a 50 day moving average price of $186.31 and a 200 day moving average price of $201.80. The company has a debt-to-equity ratio of 2.12, a quick ratio of 0.84 and a current ratio of 0.84.

IQVIA (NYSE:IQV) last issued its earnings results on Thursday, February 6th. The medical research company reported $2.90 earnings per share for the quarter, missing the consensus estimate of $3.11 by ($0.21). IQVIA had a return on equity of 28.81% and a net margin of 8.91%. Sell-side analysts expect that IQVIA Holdings Inc. will post 10.84 earnings per share for the current year.

Analyst Upgrades and Downgrades

Several analysts have recently issued reports on IQV shares. Morgan Stanley upped their target price on shares of IQVIA from $245.00 to $250.00 and gave the company an “overweight” rating in a research report on Tuesday, February 11th. Stifel Nicolaus lowered their price objective on IQVIA from $273.00 to $261.00 and set a “buy” rating for the company in a research note on Friday, February 7th. BTIG Research cut IQVIA from a “buy” rating to a “neutral” rating in a report on Monday, February 3rd. Bank of America lowered their price target on IQVIA from $255.00 to $235.00 and set a “buy” rating for the company in a research report on Friday, December 13th. Finally, Truist Financial reiterated a “buy” rating and set a $263.00 price objective (up previously from $261.00) on shares of IQVIA in a research report on Monday, February 10th. Five research analysts have rated the stock with a hold rating, sixteen have issued a buy rating and one has issued a strong buy rating to the stock. Based on data from MarketBeat, IQVIA presently has a consensus rating of “Moderate Buy” and a consensus target price of $249.05.

About IQVIA

IQVIA Holdings Inc engages in the provision of advanced analytics, technology solutions, and clinical research services to the life sciences industry in the Americas, Europe, Africa, and the Asia-Pacific. It operates through three segments: Technology & Analytics Solutions, Research & Development Solutions, and Contract Sales & Medical Solutions.